Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. (KPTI) Stock Overview
Explore Karyopharm Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
38.3M
P/E Ratio
-0.58
EPS (TTM)
$-11.87
ROE
0.37%
KPTI Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Karyopharm Therapeutics Inc. (KPTI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 50.48, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $6.90.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.58 and a market capitalization of 38.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.